GUIDEPOINT
LIVE

Serial Number

98910926

Owner

ADELA, INC.

Attorney

Ryan S. Hilbert

Filing Date

Dec 18, 2024

Add to watchlist:

No watchlists yet
View on USPTO

GUIDEPOINT Trademark

Serial Number: 98910926

GUIDEPOINT is a trademark filed by ADELA, INC. on December 18, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

ADELA, INC.

353 Hatch Drive
Foster City, CA 94404

Entity Type: 03

Trademark Details

Filing Date

December 18, 2024

Registration Date

Not Registered

Goods & Services

Laboratory testing services, namely, clinical processing of medical diagnostic testing kits; Providing temporary use of non-downloadable software for use in creating, displaying, sharing and storing test results in the fields of cancer and prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases; all of the preceding excluding pharmacy services and retail sales of prescription and over-the-counter pharmaceuticals of third parties

Medical testing for diagnostic or treatment purposes; Medical diagnostic testing, monitoring, and reporting services; Consulting services in the fields of diagnostic medical testing; Providing medical consultancy and advisory services; Providing medical testing services in the fields of cancer and prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases for diagnostic or treatment purposes; Medical testing services, namely, diagnostic testing services for detecting cancer and prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases by identifying and analyzing biomarkers for diagnostic or treatment purposes; Providing medical screening, detection being medical testing, and monitoring services for cancer and prenatal, cardiovascular and autoimmunity anomalies, disorders and diseases; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories, namely, clinical processing of medical diagnostic testing kits, all of the preceding excluding pharmacy services and retail sales of prescription and over-the-counter pharmaceuticals of third parties

Medical diagnostic tests comprised of assays and reagents that test for the presence of medical biomarkers present in human blood and body fluids by applying advanced analytics; Medical diagnostic tests comprised of assays and reagents that test for the presence of medical biomarkers present in human blood and body fluids by applying machine learning technology; Medical diagnostic test strips for blood analysis, urine analysis, saliva analysis, water analysis, and liquid biopsy; Diagnostic assays, reagents, enzymes, and nucleotides for medical and clinical purposes, namely, for testing blood and body fluids, all of the preceding excluding pharmacy services and retail sales of prescription and over-the-counter pharmaceuticals of third parties

Blood collection kit comprised of blood collecting tubes; Blood testing apparatus; Diagnostic apparatus for medical purposes, namely, diagnostic kits consisting primarily of probes, buffers and reagents for use in liquid biopsy testing; Diagnostic tests comprising medical apparatus and instruments, namely, liquid biopsy testing systems comprised of diagnostic apparatus for medical purposes used in medical laboratories for testing blood and body fluids; Medical diagnostic testing kits comprised primarily of sterile medical specimen collection tools in the nature of lancets, saliva collection tubes, collection cards, and swabs for the collection of blood, urine, saliva, and feces for use in testing and for monitoring various medical conditions, and also including printed instructions and return shipping packaging, all of the preceding excluding pharmacy services and retail sales of prescription and over-the-counter pharmaceuticals of third parties

Filing History

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 14, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 14, 2026 GNSL
SUSPENSION LETTER WRITTEN
Jul 14, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 16, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 16, 2026 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 16, 2026 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 20, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 20, 2026 GNSL
SUSPENSION LETTER WRITTEN
Feb 20, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 23, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 23, 2026 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jan 23, 2026 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sep 18, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Sep 18, 2025 GNSL
SUSPENSION LETTER WRITTEN
Sep 18, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 21, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 21, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 21, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 9, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jun 9, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jun 9, 2025 CNRT
ASSIGNED TO EXAMINER
Jun 5, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 27, 2025 NWOS
NEW APPLICATION ENTERED
Dec 18, 2024 NWAP